Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.90 EUR
Change Today +0.002 / 0.07%
Volume 1.2M
SRN On Other Exchanges
Symbol
Exchange
BrsaItaliana
As of 11:30 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

sorin spa (SRN) Snapshot

Open
€2.92
Previous Close
€2.90
Day High
€2.92
Day Low
€2.86
52 Week High
03/6/15 - €3.07
52 Week Low
10/15/14 - €1.63
Market Cap
1.4B
Average Volume 10 Days
3.4M
EPS TTM
€0.11
Shares Outstanding
478.7M
EX-Date
--
P/E TM
26.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for SORIN SPA (SRN)

Related News

No related news articles were found.

sorin spa (SRN) Related Businessweek News

No Related Businessweek News Found

sorin spa (SRN) Details

Sorin S.p.A. develops, produces, and distributes medical devices for cardiac surgery and for the treatment of cardiac rhythm dysfunctions. It offers disposable biomedical devices and systems, including heart-lung machines; cardiopulmonary systems, such as oxygenators and custom packs; autotransfusion systems and disposables; perfusion tubing systems; cannulae; and endoscopic vessel harvesting systems for extracorporeal circulation during surgery. The company also provides mechanical heart valves, tissue heart valves, self-anchoring tissue heart valves, and annuloplasty rings to replace or repair dysfunctional heart valves or treat congenital diseases. In addition, it offers implantable devices, monitoring systems, and accessories to treat cardiac rhythm dysfunctions that comprise pacemakers, implantable defibrillators, systems to treat heart failure (CRT-D), programmers, electrodes, electrophysiology leads, and Holter monitors; and disposable medical devices for urology, urodynamics, heart surgery, and haemodialysis. The company sells its products worldwide primarily under the Sorin Biomedica, Dideco, Stöckert, Cobe Cardiovascular, Ela Medical, and Carbomedics brand names. Sorin S.p.A. was founded in 2004 and is headquartered in Milan, Italy.

3,900 Employees
Last Reported Date: 03/16/15
Founded in 2004

sorin spa (SRN) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €789.0K
Chairman, President and Chairman of Executive...
Total Annual Compensation: €629.0K
Compensation as of Fiscal Year 2013.

sorin spa (SRN) Key Developments

Sorin S.p.A. Reports Consolidated and Parent Earnings Results for the Year 2014; Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Year 2015

Sorin S.p.A. reported consolidated and parent earnings results for the year 2014. For the year, on consolidated basis, EBITDA was €121.0 million, or 16.2% of revenues, compared to €131.1 million, or 17.8% of revenues in 2013. EBITDA included a €7.2 million impact from New Ventures and reflected a €14.0 million unfavorable foreign exchange effect. EBIT was €73.7 million compared to €68.6 million in 2013. EBIT before special items was €73.4 million in 2014 compared to €82.8 million in 2013. Special items, positive for €0.4 million in 2014, primarily included restructuring charges for €1.5 million and €7.9 million related to the impact from the sales return reserve, balanced by a €15.5 million income related to the insurance indemnification for the earthquakes in Emilia of 2012. Net profit was €52.0 million compared to €48.9 million in 2013. The net profit for 2014 includes €15.5 million, considered the minimum insurance payment due to the company in relation to the damage caused by the 2012 earthquakes. Adjusted net profit was €55.1 million, compared to €60.8 million in 2013. Adjusted net profit included a €5.3 million impact from New Ventures and reflected a €10.0 million unfavorable foreign exchange effect. Net financial debt as of December 31, 2014 was €124.4 million, compared to €68.7 million as of December 31, 2013. Free cash flow amounted to €5.0 million, reflecting one-off investments related to the reconstruction of the Mirandola site and a temporary absorption in working capital. For the year, on parent basis, the company recorded a net profit of €46.5 million against €28.5 million in 2013. For 2015, the company expects revenues to grow by 4% to 6% over 2014 and adjusted net profit of approximately €55 million, equivalent to adjusted EPS of 11.5 cents, substantially in line with 2014. The company expects the temporary dilutive effect of the New Ventures to be in the region of €10 million (of which approximately €3 million incremental compared to 2014) at EBITDA level. For the first quarter of 2015, the company expects revenues to grow 2% to 3% over the same period of 2014.

Sorin Group Reports Preliminary Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year 2015

Sorin Group reported preliminary unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenues of €196.5 million, up 5.0% compared to the fourth quarter of 2013. Adjusted net profit was €21.0 million compared to €22.8 million in the fourth quarter of 2013. For the year, the company's revenues were €746.9 million, up 3.4% compared to 2013. Adjusted net profit was €55.1 million compared to €60.8 million in 2013. EBITDA was €120.7 million, or 16.2% of revenues, compared to €131.1 million, or 17.8% of revenues in 2013. EBIT was €74.1 million compared to €68.6 million in 2013. Net profit was €52.5 million compared to €48.9 million in 2013. Free cash flow amounted to €2.2 million. Net financial debt as of December 31, 2014 was €124.4 million, compared to €113.2 million as of September 30, 2014. For the first quarter of 2015, the company expects revenues to grow 2% - 3% over the same period of 2014. For the year 2015, the company expects revenues to grow 4% - 6% over 2014 and Adjusted net profit substantially in line with 2014.

Sorin SpA, Board Meeting, Mar 16, 2015

Sorin SpA, Board Meeting, Mar 16, 2015. Agenda: To consider the final draft of the financial statements for 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRN:IM €2.90 EUR +0.002

SRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Edwards Lifesciences Corp $130.97 USD -7.36
InspireMD Inc $0.28 USD +0.0155
Smith & Nephew PLC 1,168 GBp -16.00
Stentys €5.75 EUR -0.12
Zimmer Holdings Inc $116.61 USD -2.15
View Industry Companies
 

Industry Analysis

SRN

Industry Average

Valuation SRN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 24.0x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORIN SPA, please visit www.sorin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.